Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study
2025

Sedated vs. Unsedated Gastroscopy in Gastric Cancer Patients

Sample size: 673 publication Evidence: moderate

Author Information

Author(s): Yin Chengke, Sun Yiwu, Liang Jie, Sui Xin, He Zhaoyi, Song Ailing, Xu Wenjia, Zhang Lei, Sun Yufei, Zhao Jingshun, Han Fei

Primary Institution: Harbin Medical University Cancer Hospital

Hypothesis

Does the type of gastroscopy (sedated vs. unsedated) affect survival outcomes in gastric cancer patients after surgery?

Conclusion

There is no significant difference in survival outcomes or distant metastases between sedated and unsedated gastroscopy in gastric cancer patients after surgery.

Supporting Evidence

  • 673 patients were enrolled in the study, with 160 in the sedated group and 513 in the unsedated group.
  • After propensity score matching, there were no significant differences in survival outcomes between the two groups.
  • The study confirmed that sex, pathological TNM stage, Borrmann type, adjuvant treatment, and surgical resection range were independent factors affecting survival outcomes.

Takeaway

This study found that whether patients with stomach cancer have a sedated or unsedated gastroscopy doesn't change their chances of surviving after surgery.

Methodology

This was a retrospective study comparing survival outcomes of patients with gastric cancer who underwent either sedated or unsedated gastroscopy, using propensity score matching to balance baseline variables.

Potential Biases

Potential selection bias due to the retrospective nature and the exclusion of patients with certain conditions.

Limitations

The study was a single-center retrospective analysis, which may limit the generalizability of the findings and could be influenced by unmeasured confounders.

Participant Demographics

Patients diagnosed with gastric cancer who underwent gastrectomy between January 2013 and December 2017.

Statistical Information

Confidence Interval

95% CI: 0.531–1.091 for overall survival before PSM; 95% CI: 0.564–1.355 after PSM.

Digital Object Identifier (DOI)

10.1186/s12885-024-13413-0

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication